Robbins LLP Invites IBRX Investors to Participate in Class Action Against ImmunityBio, Inc.

Robbins LLP Invites IBRX Investors to Act

Robbins LLP has taken a significant step toward representing shareholders who invested in ImmunityBio, Inc. (NASDAQ: IBRX) during a critical period between January 19, 2026, and March 25, 2026. Following revelations that the company’s lead product candidate, Anktiva, might not perform as advertised, the firm has initiated a class action lawsuit to seek justice for those affected by the situation.

Background of the Case

ImmunityBio is a biotechnology firm known for its innovative approaches to treating various diseases, including cancer. The company's lead product candidate, Anktiva, was marketed for certain types of bladder cancer. However, the lawsuit alleges that the company’s management, particularly founder Soon-Shiong, has misled investors regarding the true capabilities and safety profile of Anktiva.

Allegations Made

The class action complaint highlights that Soon-Shiong significantly overstated Anktiva's effectiveness, suggesting it could cure and prevent all cancers. This misleading information created false hope and risked investor capital. The situation escalated dramatically when a warning letter from the U.S. Food and Drug Administration (FDA) was made public on March 24, 2026. The letter outlined several misleading statements made by Soon-Shiong, further alarming investors.

Financial Impact

As a direct consequence of the FDA's warning, ImmunityBio's stock price witnessed a drop, plummeting by $1.98 or 21%, ultimately closing at $7.42 per share. This plunge reflects the immediate financial repercussions faced by investors, many of whom are now seeking restitution for their losses.

Who Can Participate?

Robbins LLP is encouraging all shareholders who acquired ImmunityBio stocks within the specified period to consider joining this class action lawsuit. Those interested in serving as lead plaintiffs must file their applications with the court by May 26, 2026. Becoming a lead plaintiff enables investors to represent the interests of the entire class, guiding the proceedings and seeking compensation for the damages incurred. Notably, investors do not need to actively participate in the lawsuit to be eligible for any potential recovery; they can remain part of the class and still receive compensation if the action is successful.

Taking Action

Individuals who fit the criteria set forth by Robbins LLP are urged to reach out for further information. The firm offers various avenues for communication, including an online form, direct email to attorney Aaron Dumas, Jr., or a dedicated phone line (800-350-6003). The representation provided by Robbins LLP operates on a contingency fee basis, meaning clients are responsible for no fees or expenses unless they win.

About Robbins LLP

Established in 2002, Robbins LLP is recognized as a leader in shareholder rights litigation. The firm is committed to aiding investors in recovering losses, advocating for improved corporate governance, and holding corporate executives accountable for misconduct. Their experience and dedication make them a trusted ally for shareholders navigating the complexities of class action claims.

Stay Informed

Shareholders who wish to keep up with the developments of the class action against ImmunityBio can sign up for notifications through Robbins LLP’s Stock Watch program, which alerts investors when there’s news concerning corporate malfeasance.

For further details about the class action or to join the fight for fairness and transparency in corporate practices, contact Robbins LLP today and empower your voice as a shareholder.